INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Apr 20, 2020 |
EVP General Counsel and Secret
Trans History: 181
|
EVP General Counsel and Secret | Form 4 | Open market or private sale of non-derivative or derivative security | 669 | $567.30 | 15,547 |
| May 07, 2020 |
EVP & General Mgr Industrial O
Trans History: 359
|
EVP & General Mgr Industrial O | Form 4 | Open market or private sale of non-derivative or derivative security | 3,753 | $567.35 | 31,991 |
| May 11, 2020 |
EVP Research and Development
Trans History: 660
|
EVP Research and Development | Form 4 | Open market or private sale of non-derivative or derivative security | 312 | $567.50 | 16,373 |
| May 21, 2020 |
Director, Chairman of the Board
Trans History: 742
|
Director, Chairman of the Board | Form 4 | Open market or private sale of non-derivative or derivative security | 9,138 | $567.51 | 337,537 |
| Jul 01, 2021 |
Director
Trans History: 524
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 13 | $567.56 | 23,504 |
| May 12, 2020 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Open market or private sale of non-derivative or derivative security | 9,359 | $567.57 | 587,261 |
| May 07, 2020 |
Director
Trans History: 44
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 646 | $567.58 | 1,265 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 617
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 1,350 | $567.61 | 579,816 |
| Nov 05, 2015 |
EVP Research and Development
Trans History: 660
|
EVP Research and Development | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 4,047 | $567.63 | 92,982 |
| Nov 05, 2015 |
EVP Research and Development
Trans History: 660
|
EVP Research and Development | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 39,605 | $567.63 | 53,377 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.